Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Rare Biomarkers Specimen Collection And Stabilization Market By 2029?

The rare biomarkers specimen collection and stabilization market has experienced substantial growth in recent years. This market is set to increase from $32.01 billion in 2024 to $35.29 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion has been driven by the human genome project, a surge in cancer research, investments in pharmaceutical R&D, the development of genomics and proteomics, and enhanced data management and bioinformatics.

The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion over the upcoming years, with its size predicted to reach $51.22 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected increase during the forecast period is fueled by several factors, including the wider application of liquid biopsy, heightened consumer awareness and demand, the growing preference for non-invasive techniques, and advancements in biomarker discovery for rare diseases. Key trends anticipated during this period encompass developments in preservation technology, an upsurge in genomic and proteomic research, the rise of point-of-care testing, improvements in regulatory frameworks and standardization, alongside enhanced data analytics and the integration of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

What Are The Key Drivers Of Growth In The Rare Biomarkers Specimen Collection And Stabilization Market?

The expanding incidence of cancer is anticipated to fuel expansion within the rare biomarker specimen collection and stabilization market in the future. Cancer constitutes a category of illnesses characterized by the unchecked multiplication and dissemination of atypical cells. The increase in cancer’s occurrence stems from environmental contaminants and lifestyle habits, including smoking and unhealthy dietary selections, which aggravate existing genetic susceptibilities. Employing rare biomarker specimen collection and stabilization techniques in studies concerning cancer prevalence allows for more precise identification and tracking of particular cancer forms, thereby improving diagnostic and treatment strategies. As an illustration, a report released in October 2023 by the European Commission, a governing body located in Europe, revealed that new cancer diagnoses climbed to 2.74 million in 2022, representing a 2.3% rise compared to 2020. Consequently, the expanding incidence of cancer is serving as a primary impetus for the development of the rare biomarker specimen collection and stabilization market.

Which Key Segments Fueling The Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilizationmarket covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA); Circulating Tumor Cells (CTCs); Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma; Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT); Oncology; Transcriptomics; Pharmacogenomics; Transplant Rejection; Population Screening; Cardiovascular Diseases; Other Applications

4) By End-User: Hospitals; Perinatal Clinics; Public Health Labs; Private Or Commercial Labs; Physician Labs; Research Institutes; Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA; Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood; CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma; Exosomes From Serum

Which Ongoing Trends Are Expected To Shape The Rare Biomarkers Specimen Collection And Stabilization Market Outlook?

Leading companies in the rare biomarker specimen collection and stabilization market are concentrating on developing innovative solutions, such as pre-analytical platforms, to automate the preparation of plasma and cell samples for multiomic liquid biopsy. These platforms provide consistent, automated fresh sample preparation at the exact time of blood collection. They allow for full autonomous processing of whole blood without requiring special tubes or skilled personnel, thereby maintaining sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the inaugural fully automated, standardized pre-analytical platform. This platform offers distinct features like precise sample handling, effective separation of plasma for cellular fractions, and immobilization of white blood cells on SmartBioSurface slides. Additionally, the platform integrates a quality control scoring system for the objective assessment of sample stability. This approach enables the systematic scoring of proteomics and metabolomics data sets to ascertain the stability of plasma and serum samples.

Which Major Industry Participants Are Leading The Rare Biomarkers Specimen Collection And Stabilization Market Growth?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

What Are The Key Regional Factors Influencing The Rare Biomarkers Specimen Collection And Stabilization Market Growth?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Rare Biomarkers Specimen Collection And Stabilization Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2025, By The Business Research Company

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model